{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:52:25Z","timestamp":1771455145434,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Malignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We established several patient-derived xenograft (PDX) models and primary cell lines of MPM. The cell lines were used to study the effects of apatinib on proliferation, cell cycle, migration, and apoptosis by CCK8, flow cytometry, wound-healing, Transwell, DAPI staining, and caspase-3 assays, respectively. For <jats:italic>in vivo<\/jats:italic> study, apatinib was delivered by gastric gavage into PDX models, and then efficacy and toxicity were determined by experimental peritoneal cancer index (ePCI) score and pathological examinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our results showed that apatinib significantly inhibited the proliferation and migration of MPM cells <jats:italic>in vitro<\/jats:italic> and induced cell cycle arrest. Studies on PDX models concurred that apatinib effectively suppressed subphrenic and liver invasions of nude mice. Moreover, histopathological analysis found that lymphocyte infiltration, coagulation necrosis and eosinophilic cell fragments were detected in tumor tissues after apatinib treatment. Apatinib showed no obvious effects on body mass of models and did not affect function of important organs, except for occasional focal lymphoid infiltration of liver (16.7%) and cardiac muscle (16.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> study.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2020.585079","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T06:04:29Z","timestamp":1607321069000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhi-Ran","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Gao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Mei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009093","article-title":"Analysis of current trends in United States mesothelioma incidence","volume":"145","author":"Price","year":"1997","journal-title":"Am J Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2014_053","article-title":"Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma","volume":"61","author":"Kaya","year":"2014","journal-title":"Neoplasma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2006.03.012","article-title":"Comprehensive management of diffuse malignant peritoneal mesothelioma","volume":"32","author":"Sugarbaker","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.09.010","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma","volume":"35","author":"Yano","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2264-z","article-title":"The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study","volume":"19","author":"Hompes","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-010-0531-7","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years\u2019 experience of a new centre for peritoneal surface malignancies","volume":"12","author":"Bretcha-Boix","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","article-title":"Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies","volume":"10","author":"Li","year":"2010","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.050310","article-title":"Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans","volume":"41","author":"Ding","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16293","article-title":"Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/1471-2407-14-820","article-title":"Multicenter phase II study of apatinib in non-triplenegative metastatic breast cancer","volume":"14","author":"Hu","year":"2014","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebocontrolled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.010","article-title":"Apatinib exerts anti-tumour effects on ovarian cancer cells","volume":"153","author":"Ding","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12967-018-1421-y","article-title":"Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia","volume":"16","author":"Deng","year":"2018","journal-title":"J Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013105","article-title":"Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report","volume":"97","author":"Du","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2766","article-title":"Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil","volume":"9","author":"Lin","year":"2020","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26596","article-title":"Cathepsin b cleavable novel prodrug ac-phe-lys-pabc-adm enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: An experimental study","volume":"118","author":"Shao","year":"2012","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2407-7-104","article-title":"Reduction of peritoneal carcinomatosis by intraperitoneal administration of phospholipids in rats","volume":"7","author":"Otto","year":"2007","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/or.3.3.483","article-title":"A patient-like human malignant pleural mesothelioma nude-mouse model","volume":"3","author":"Astoul","year":"1996","journal-title":"Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2011.02778.x","article-title":"A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma","volume":"62","author":"Enomoto","year":"2012","journal-title":"Pathol Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2011-200631","article-title":"Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma","volume":"65","author":"Enomoto","year":"2012","journal-title":"J Clin Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","article-title":"BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma","volume":"13","author":"Alakus","year":"2015","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.05.046","article-title":"Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer","volume":"431","author":"Cheng","year":"2018","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell Signal"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.014","article-title":"Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer","volume":"372","author":"Roviello","year":"2016","journal-title":"Cancer Lett"},{"key":"B26","article-title":"Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K\/Akt Signaling Pathway","volume":"24","author":"Jia","year":"2019","journal-title":"J BUON"},{"key":"B27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-018-0870-3","article-title":"Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2\/RAF\/MEK\/ERK and PI3K\/AKT pathways in cholangiocarcinoma cell","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/092986708783955446","article-title":"Molecular Targets and Targeted Therapies for Malignant Mesothelioma","volume":"15","author":"Palumbo","year":"2008","journal-title":"Curr Med Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000101","article-title":"Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy","volume":"2","author":"Dolly","year":"2017","journal-title":"ESMO Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1179","article-title":"Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells","volume":"6","author":"Yamaji","year":"2017","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2015.1016686","article-title":"A new role for the PI3K\/Akt signaling pathway in the epithelial-mesenchymal transition","volume":"9","author":"Xu","year":"2015","journal-title":"Cell Adh Migr"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.585079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T06:04:31Z","timestamp":1607321071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.585079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":32,"alternative-id":["10.3389\/fonc.2020.585079"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.585079","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]},"article-number":"585079"}}